Table 1. Selected preclinical and... | American Society of Hematology

Table 1.

Selected preclinical and clinical use of cellular therapies in GVHD

Cell	Species mouse (m)/human (h)	Origin recipient (r)/donor (d)	GVHD	GVL	Reference (examples)
nTreg	m h	d; r; 3rd party	↓↓↓		83,84,-86,88
			↓↓/ongoing	→	84,85
				↓	88
				Ongoing	90
iTreg (CD4)	m h	d	↑		88
			↓	↓	88,94
			→	Ongoing	87
			Ongoing		88,94
iTreg (CD8)	m	r	↑		88
			↓	↑	94,98
				→	94
					98
Tr1	m h	d	↓		104
			Ongoing	ND	105
				Ongoing
ILC2	m	d	↓↓		56
ILC2	m	d	↓↓	→	56
NK	m h	D	↓		61,-63
			→	↑	61,63
			↑	→	62
				↑	119,120
					64,121
					120,121
iNKT	m	d, 3rd party	↓↓		57,70,122
iNKT	m	d, 3rd party		→	57,122
MDSC	m	d	↓↓		46,47,50,51
MDSC	m	d	↓↓	→	47,51
MSC	m h	d d, 3rd party	↓↓		12,29
			→	ND	20,,,,,,,-28,31,-33
				ND
MAPC	m h	d 3rd party	↓↓		40,41
			↓↓	ND	42
				ND

Cell	Species mouse (m)/human (h)	Origin recipient (r)/donor (d)	GVHD	GVL	Reference (examples)
nTreg	m h	d; r; 3rd party	↓↓↓		83,84,-86,88
			↓↓/ongoing	→	84,85
				↓	88
				Ongoing	90
iTreg (CD4)	m h	d	↑		88
			↓	↓	88,94
			→	Ongoing	87
			Ongoing		88,94
iTreg (CD8)	m	r	↑		88
			↓	↑	94,98
				→	94
					98
Tr1	m h	d	↓		104
			Ongoing	ND	105
				Ongoing
ILC2	m	d	↓↓		56
ILC2	m	d	↓↓	→	56
NK	m h	D	↓		61,-63
			→	↑	61,63
			↑	→	62
				↑	119,120
					64,121
					120,121
iNKT	m	d, 3rd party	↓↓		57,70,122
iNKT	m	d, 3rd party		→	57,122
MDSC	m	d	↓↓		46,47,50,51
MDSC	m	d	↓↓	→	47,51
MSC	m h	d d, 3rd party	↓↓		12,29
			→	ND	20,,,,,,,-28,31,-33
				ND
MAPC	m h	d 3rd party	↓↓		40,41
			↓↓	ND	42
				ND

ND, not determined.